Scoping paper on the potential risk(s) of Garcinia cambogia oral consumption
Questions to the Committee
TOX/2025/41
In this guide
In this guideThis is a discussion paper. It does not reflect the views of the Committee. It should not be cited.
198. The Committee are asked to consider the following questions:
a) Does the Committee agree with the conclusions reached by ANSES?
b) Based on the current data, is the Committee able to identify a no-observed effect level or any other options, to derive a health-based guidance value?
i) If no, what additional information would the Committee require to provide a risk assessment?
c) Does the Committee have any other comments?
October 2025
Secretariat